¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023³â Á¦6Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2023-06-03

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023³â Á¦6Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2023-06-03
±³À°ÀÏÀÚ : 2023-06-03
±³À°Àå¼Ò : ¼­¿ï ½ºÀ§½º±×·£µåÈ£ÅÚ

±³À°ÁÖÁ¦ : 2023³â Á¦6Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À°

ÁÖÃÖ±â°ü : ´ëÇѳ»°úÇÐȸ
´ã´çÀÚ : ´ëÇѳ»°úÇÐȸ
¿¬¶ôó : 02-793-4364  

À̸ÞÀÏ : kaim4364@kaim.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 31 ½Ã°£ 40ºÐ

¼¼ºÎ¼ö°­·á : 70,000¿ø  

ºñ°í »çÀüµî·Ï: (³»°úÀü°øÀÇ¡¤Àü¹®ÀÇ) 40,000¿ø / (Ÿ°ú/ºñȸ¿ø) 60,000¿ø / ´çÀϵî·Ï: (³»°úÀü°øÀÇ¡¤Àü¹®ÀÇ) 50,000¿ø / (Ÿ°ú/ºñȸ¿ø) 70,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 08:30~08:55 Recent Update on the Management of Chronic Viral Hepatitis °­¹Î±Ô(¿µ³²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 08:55~09:20 Recent Update on the Management of Hepatocellular Carcinoma ÀÌÇѾÆ(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 09:20~09:45 Diagnosis and Treatment of Asymptomatic Gallbladder Disease ÀÌ°æÁÖ(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 09:45~10:10 Approach of Asymptomatic CA 19-9 Elevation ¹ÚÅ¿µ(Áß¾ÓÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 10:30~11:00 Diagnosis and Treatment of Colon Subepithelial Lesion ±è¼ºÁß(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 11:00~11:30 Recent Update on the Post-Polypectomy Surveillance À±¼ø¸¸(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 11:30~12:00 Diagnosis and Management of GERD ¹ÚÂùÇõ(ÇѾçÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 12:00~12:30 Diagnosis and Management of H. pylori Infection ÀÌ»óÇ¥(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 08:30~09:00 What Are the Key Changes and Implication for Clinical Practice in COPD (GOLD guideline 2023)? ÀÌâ·ü(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 09:00~09:30 IPF and Progressive Pulmonary Fibrosis (PPF) ¼ÛÁø¿ì(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 09:30~10:00 Recent Treatment Strategy for MDR-Tb ½Éż±(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 10:30~11:00 Pathophysiology of Cough and Updated Treatment of Chronic Refractory Cough ¾ÈÅÂÁØ(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 11:00~11:30 Biologics in Airway Diseases ¹ÚÇýÀ±(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 11:30~12:30 Targeted Treatment of NSCLC ¿©Ã¢µ¿(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 08:30~09:00 Transplantation Immunology Overview ±è¸í±Ô(°í·ÁÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 09:00~09:30 Pre-Transplant Evaluation of Donor and Recipient ±èÈ¿Áø(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 09:30~10:00 Basics in Immunosuppressant for KT ¿ÀÅ·Å(Àü³²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 10:30~11:00 Desensitization in ABO and HLA–incompatible KT Á¶ÀåÈñ(°æºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 11:00~11:30 Evaluation and Management of Antibody-Mediated Rejection ÀÌÁ¤Ç¥(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 11:30~12:00 Prevention and Management of Infectious Complication in KT recipients ÇÔ¿µ·Ï(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 12:00~12:30 Management of Pre and Post-Transplant Malignancy in KT recipients ±èÅÂÈñ(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 08:30~09:00 Respiratory Infection in Immunocompromised Host: RSV, Parainfluenza, Metapneumovirus Infection È«È¿¸²(´ë±¸°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 09:00~09:30 Gastrointestinal Infection: Non-Typhoidal Salmonella, Campylobacter and Other Gastrointestinal Infection À̽¼ø(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 09:30~10:00 Mosquito-Borne Diseases, Malaria, Dengue, Chikungunya, & Zika Virus ÀÓÀçÇü(ÀÎÇÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 10:30~11:10 Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults ±èÁöÀº(ÇѾçÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 11:10~11:50 Strategies to Prevent Ventilator-Associated Pneumonia, Ventilator-Associated Events, and Nonventilator Hospital-Acquired Pneumonia in Acute-Care Hospitals: 2022 Update Çã°æ¹Î(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 11:50~12:30 SHEA Statement on Stewardship during Public Health Emergencies, Antibiotic Stewardship lecture for junior staff ±è¿ëÂù(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 13:30~14:00 Current Guidelines for Acute Coronary Syndrome À±ÇõÁØ(°è¸íÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 14:00~14:30 Current Guidelines for Atrial Fibrillation ¹ÚÁ¾¼º(µ¿¾ÆÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 14:30~15:00 Current Guidelines for Heart Failure À±Á¾Âù(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 15:30~16:00 Update on Management of Dyslipidemia ¿À±Ôö(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 16:00~16:30 Update on Valvular Heart Disease ȲÈñÁ¤(°æÈñÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 16:30~17:00 Update on Bradyarrhythmia °íÁ¡¼®(¿ø±¤ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦2ȸÀÇÀå 17:00~17:30 Update on Artificial Intelligence in Cardiovascular Field À±´ö¿ë(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 13:30~14:00 Diagnosis of Critical Illness–induced Corticosteroid Insufficiency ±èÈ¿Á¤(À»ÁöÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 14:00~14:30 Primary Aldosteronism 2023 Update À̽ÂÈÆ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 14:30~15:00 Update on the Diagnosis and Management of PCOS ÀÌÇýÁø(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 15:30~16:00 Bird¡¯s Eye View on Lipid and Human Health - Beyond Atherosclerosis ¹Ú¿µ¹Ì(ÀÌÈ­ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 16:00~16:30 Final Destination: Targeting LDL Cholesterol Á¤Ã¢Èñ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 16:30~17:00 What¡¯s New in Obesity Treatment ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦5ȸÀÇÀå 17:00~17:30 Contemporary Guideline for Fatty Liver Disease ÀÌ¿ëÈ£(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 13:30~14:00 Recent Advances in TMA (TTP) ÀÓÈ£¿µ(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 14:00~14:30 Recent Advances in MDS È«ÁؽÄ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 14:30~15:00 Recent Advances in CML ±è°æÇÏ(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 15:30~16:00 Modification of Anticancer Drug in Patients with Renal Impairment ±èÀÎÈ£(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 16:00~16:30 Modification of Anticancer Drug in Patients with Hepatic Impairment ¿À¼Ò¿¬(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 16:30~17:00 Anticancer Treatment in Patients with Autoimmune/Pulmonary Disease ±ÇÁ¤Çý(Ãæ³²ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦1ȸÀÇÀå 17:00~17:30 Anticancer Treatment in Elderly Patients with Cancer ±èÁöÇö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 13:30~14:15 New Biologic Therapies for Difficult-to-Treat Allergy Diseases ¾ç¹Î¼®(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 14:15~15:00 Current and Emerging Biologic and Small Molecule Therapies for Atopic Dermatitis ±è¹Ì¾Ö(Â÷ÀÇ°úÇдëÇÐ)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 15:30~16:10 Recent Update on the Diagnosis and Management of Angioedema ±è¼öÁ¤(°æºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 16:10~16:50 A Hands-on Approach to Allergic Contact Dermatitis and Patch Testing ±è¼ºÁø(Àü³²ÀÇ´ë ÇǺΰú)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦3ȸÀÇÀå 16:50~17:30 Diagnosis and Management of Insect Allergy ½ÅÀ¯¼·(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 13:30~14:00 Update of Axial Spondyloarthritis ¹Ú¹ÎÂù(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 14:00~14:30 Treatment of Systemic Sclerosis and Pulmonary Arterial Hypertension ±è±âÁ¶(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 14:30~15:00 Update of Gout and CPPD ÃÖÀ±Á¤(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 15:30~16:00 A Case of Macrophage Activation Syndrome During the Treatment of Adult-onset Still¡¯s Disease with Tocilizumab ÃÖ¼¼¸²(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 16:00~16:30 Idiopathic Inflammatory Arthritis in the Auditory Canal in a Patient with Hearing Impairment ¾È¼ö¹Î(¿ï»êÀÇ´ë)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 16:30~17:00 Overlap Syndrome of Systemic Sclerosis and Cryoglobulinemic Vasculitis with Central Nervous System Involvement Á¤À¯Áø(¼­¿ïÀÇ·á¿ø)

±³À°½Ã°£ 06¿ù 03ÀÏ Á¦4ȸÀÇÀå 17:00~17:30 Tumor-like Presentation of Cerebral Vasculitis in a Patient with Systemic Lupus Erythematosus: A Biopsy-confirmed Case °­Á¾¿Ï(´ë±¸ÆÄƼ¸¶º´¿ø)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023³â Á¦6Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2023-06-03""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û °­¿øÁöȸ ´ç´¢º´ ±³À°ÀÚ ¼¼¹Ì³ª : 2023-06-03
´ÙÀ½±Û Á¦21ȸ ÇǺκ´¸®½ÉÆ÷Áö¾ö (Inflammatory Skin Disease) : 2023-06-03
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21191 ¼­¿ï ´ëÇÑÀÓ»óÃÊÀ½ÆÄÇÐȸ Á¦24ȸ Ãá°èÇмú´ëȸ : 2024-08-11 0 4 15:42:17
21190 ¼­¿ï 2024³â ´ëÇÑÇǺΰúÇÐȸ ¼­¿ïÁöºÎȸ Ä¡·á ½ÉÆ÷Áö¾ö : 2024-08-03 0 3 15:40:06
21189 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-07-30 0 2 15:38:43
21188 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ(À§¿øȸ) ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À° : 2024-07-30 0 1 15:37:22
21187 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¼ºÇü¿Ü°ú °­³²Áý´ãȸ(´«Áö¹æÀ̽Ä, ºñÀý°³¹ý, Àý°³¹ý) : 2024-07-27 0 2 15:36:01
21186 ¼­¿ï 2024³âµµ ÇϹݱâ ÀÓ»óÁø·áÁöħ ±³À° ¿öÅ©¼ó : ¡¸ÀÓ»óÁø·áÁöħÀÇ °³¹ß¡¹ ½ÇÇàÇϱâ - ¹®Çå°Ë»ö°ú Áú Æò°¡ : 2024-07-27 0 1 15:34:17
21185 ´ë±¸ ¿µ³²»ý½Ä³»ºÐºñ ÇÐȸ Çмú½ÉÆ÷Áö¾ö : 2024-07-27 0 2 15:32:48
21184 ÀüºÏ ¿ø±¤´ëÇб³º´¿ø Á¦12ȸ ¿ø±¤ ½ÉÀüµµ ½ÉÆ÷Áö¿ò : 2024-07-27 0 3 15:31:42
21183 Ãæ³² 2024³â Á¦14ȸ ´ëÇÑÀü¸³¼±ÇÐȸ-´ëÇѹ财Àå¾Ö¿ä½Ç±ÝÇÐȸ °øµ¿½ÉÆ÷Áö¾ö : 2024-07-27 0 2 15:30:29
21182 °æ±â Á¦6ȸ °¡Å縯´ëÇб³ ¼ººó¼¾Æ®º´¿ø ¾Ï ½ÉÆ÷Áö¾ö(¿ÀÇÁ¶óÀÎ/¿Â¶óÀÎ) : 2024-07-26 0 1 15:29:07
21181 ´ë±¸ Çѱ¹¿©ÀÚÀÇ»çȸ ´ë±¸°æºÏÁöȸ 7¿ù Çмú½ÉÆ÷Áö¾ö(ºÒ¸éÁõ, ¼ö¸éÁ¦, Ȳ¹Ýº¯¼º ¹× ³ëÈ­ °ü·Ã ¾ÈÁúȯ) : 2024-07-23 0 7 08:16:07
21180 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ) Á¦12ȸ ¼­¿ï ÀÓ»ó¾îÁö·³Áõ ¼¼¹Ì³ª : 2024-07-21 0 7 08:14:06
21179 ¼­¿ï ¼Ò¾Æû¼Ò³âÇൿ¹ß´ÞÁõÁø ÇнÀÀå¾Ö ÇÁ·Î±×·¥ ¿öÅ©¼ó : 2024-07-21 0 8 08:12:40
21178 ¼­¿ï ´ëÇÑÁ¤Çü¿Ü°ú½ºÆ÷Ã÷ÀÇÇÐȸ - Á¦2Â÷ ½ºÆ÷Ã÷ ¼Õ»ó ½ÉÆ÷Áö¾ö : 2024-07-21 0 5 08:11:33
21177 ¼­¿ï PH Korea 2024 with 4th EASOPH(Á¦9ȸ Æó°íÇ÷¾Ð Çмú´ëȸ) (2ÀÏÂ÷) : 2024-07-20 0 2 08:09:04
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷